Xavier Hébuterne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10555921/publications.pdf

Version: 2024-02-01

93 papers 8,759 citations

57758 44 h-index 91 g-index

102 all docs $\begin{array}{c} 102 \\ \\ \text{docs citations} \end{array}$

102 times ranked

11703 citing authors

#	Article	lF	Citations
1	Role of adherent and invasive <i>Escherichia coli</i> ii>in Crohn's disease: lessons from the postoperative recurrence model. Gut, 2023, 72, 39-48.	12.1	22
2	Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. Tissue Barriers, 2023, 11, .	3.2	1
3	Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflammatory Bowel Diseases, 2022, 28, 1034-1044.	1.9	10
4	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease, 2022, 54, 309-315.	0.9	10
5	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, 1269-1280.	1.3	15
6	Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions. Alimentary Pharmacology and Therapeutics, 2022, 55, 658-669.	3.7	7
7	Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 832-840.	2.8	11
8	Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA,) Tj ETC	2q 0.@ 0 rg	BT ∮ Øverlock I
9	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. Journal of Crohn's and Colitis, 2021, 15, 938-949.	1.3	23
10	Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterology Journal, 2021, 9, 552-560.	3.8	28
11	Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial. Gastroenterology, 2021, 160, 2595-2598.e3.	1.3	32
12	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 766-773.	1.3	11
13	Faster and less invasive tools to identify patients with ileal colonization by adherentâ€invasive ⟨i⟩E. coli⟨/i⟩ in Crohn's disease. United European Gastroenterology Journal, 2021, 9, 1007-1018.	3.8	11
14	ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clinical Nutrition, 2020, 39, 632-653.	5.0	211
15	The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report. Digestive and Liver Disease, 2020, 52, 420-426.	0.9	3
16	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 1063-1075.	8.1	35
17	Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2020, 45, 101561.	1.5	4
18	Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease, 2020, 52, 740-744.	0.9	12

#	Article	IF	CITATIONS
19	Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Digestive and Liver Disease, 2020, 52, 704-720.	0.9	4
20	Motivation to pursue anti-TNFα treatment in patients with Crohn's disease – the SPACE motivation study. Digestive and Liver Disease, 2020, 52, 995-1001.	0.9	0
21	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology, 2020, 159, 139-147.	1.3	126
22	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflammatory Bowel Diseases, 2020, 26, 1562-1571.	1.9	27
23	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 896-903.	1.3	12
24	Effectiveness and tolerance of an oral nutritional supplement highly concentrated in protein and energy in elderly subjects at risk of malnutrition. Nutrition Clinique Et Metabolisme, 2020, 34, 156-160.	0.5	1
25	Nutrition anti-inflammatoire et MICIÂ: que dire à nos patientsÂ?. Nutrition Clinique Et Metabolisme, 2019, 33, 126-130.	0.5	1
26	PO81â€fRapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II. American Journal of Gastroenterology, 2019, 114, S21-S22.	0.4	0
27	Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physiciansâ€"Results of the NutriCancer2012 Study. Journal of Parenteral and Enteral Nutrition, 2018, 42, 255-260.	2.6	71
28	Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut, 2018, 67, 1824-1835.	12.1	87
29	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	4.4	80
30	Colon capsule endoscopy to screen for colorectal neoplasia inÂthose with family histories of colorectal cancer. Gastrointestinal Endoscopy, 2018, 87, 695-704.	1.0	22
31	NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer. Journal of Geriatric Oncology, 2018, 9, 74-80.	1.0	32
32	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 135-144.	13.7	157
33	French national consensus clinical guidelines for the management of Crohn's disease. Digestive and Liver Disease, 2017, 49, 368-377.	0.9	19
34	ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clinical Nutrition, 2017, 36, 321-347.	5.0	457
35	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the) Tj ETQq1 1 0. The, 2017, 389, 266-275.	.784314 rg 13.7	gBT /Overlock 353
36	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet, The, 2017, 390, 2779-2789.	13.7	633

#	Article	IF	Citations
37	Development of the IBD Disk. Inflammatory Bowel Diseases, 2017, 23, 333-340.	1.9	72
38	French national consensus clinical guidelines for the management of ulcerative colitis. Digestive and Liver Disease, 2016, 48, 726-733.	0.9	14
39	Conduite à tenir pratique pour l'exploration d'une malabsorption, d'une maldigestion, et d'une entéropathie exsudative. Nutrition Clinique Et Metabolisme, 2016, 30, 98-104.	0.5	2
40	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflammatory Bowel Diseases, 2016, 22, 1362-1369.	1.9	24
41	Nutritional support of the elderly cancer patient: Long-term nutritional support. Nutrition, 2015, 31, 617-618.	2.4	7
42	Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clinical Gastroenterology and Hepatology, 2015, 13, 1770-1775.	4.4	84
43	Nutrition et cancerÂ: pourquoi intervenir avant 5Â% de perte de poidsÂ?. Nutrition Clinique Et Metabolisme, 2015, 29, 126-131.	0.5	5
44	Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer. Cancer Research, 2015, 75, 835-845.	0.9	96
45	Bone marrow Th17 TNFî \pm cells induce osteoclast differentiation, and link bone destruction to IBD. Gut, 2015, 64, 1072-1081.	12.1	102
46	Prevalence of malnutrition in PS 0-1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients Journal of Clinical Oncology, 2015, 33, 1587-1587.	1.6	0
47	Body composition, anthropometrics, energy expenditure, systemic inflammation, in premenopausal women 1Ayear after laparoscopic Roux-en-Y gastric bypass. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 500-507.	2.4	34
48	Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment. Digestive and Liver Disease, 2014, 46, 667-674.	0.9	54
49	Prevalence of Malnutrition and Current Use of Nutrition Support in Patients With Cancer. Journal of Parenteral and Enteral Nutrition, 2014, 38, 196-204.	2.6	537
50	Methaemoglobinaemia and renal failure following mesalazine for treatment of inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 900-901.	1.3	2
51	Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study. Journal of Crohn's and Colitis, 2014, 8, 161-165.	1.3	24
52	Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 423-431.e1.	4.4	117
53	Treatment algorithms in Crohn's – Up, down or something else?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 473-483.	2.4	29
54	Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut, 2013, 62, 201-208.	12.1	147

#	Article	IF	CITATIONS
55	Impact of restrictive diets on the risk of undernutrition in a free-living elderly population. Clinical Nutrition, 2012, 31, 69-73.	5.0	39
56	Subversion of Autophagy in Adherent Invasive Escherichia coli-Infected Neutrophils Induces Inflammation and Cell Death. PLoS ONE, 2012, 7, e51727.	2.5	58
57	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut, 2011, 60, 198-203.	12.1	160
58	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2011, 5, 484-498.	1.3	93
59	Feeding the patients with upper gastrointestinal bleeding. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 197-201.	2.5	26
60	A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nature Genetics, 2011, 43, 242-245.	21.4	523
61	Clinical practice guidelines from the French health high authority: Nutritional support strategy in protein-energy malnutrition in the elderly. Clinical Nutrition, 2011, 30, 312-319.	5.0	114
62	Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. Gut, 2011, 60, 17-25.	12.1	246
63	A telephone-linked computer system for home enteral nutrition. Journal of Telemedicine and Telecare, 2010, 16, 363-367.	2.7	5
64	Amplification loop of the inflammatory process is induced by P2X ₇ R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. American Journal of Physiology - Renal Physiology, 2010, 299, G32-G42.	3.4	57
65	Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. American Journal of Physiology - Renal Physiology, 2009, 296, G1332-G1343.	3.4	54
66	ESPEN Guidelines on Parenteral Nutrition: Home Parenteral Nutrition (HPN) in adult patients. Clinical Nutrition, 2009, 28, 467-479.	5.0	365
67	ESPEN Guidelines on Parenteral Nutrition: Gastroenterology. Clinical Nutrition, 2009, 28, 415-427.	5.0	119
68	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	13.7	996
69	Sarcopenia is prevalent in patients with Crohn $\hat{E}^{1}\!\!/\!4$ s disease in clinical remission. Inflammatory Bowel Diseases, 2008, 14, 1562-1568.	1.9	116
70	Métabolisme et apports en acides aminés chez le sujet âgé. Nutrition Clinique Et Metabolisme, 2008, 22, 183-188.	0.5	2
71	Effects of age, malnutrition and refeeding on the expression and secretion of ghrelin. Clinical Nutrition, 2008, 27, 724-731.	5.0	29
72	Survival of Patients Identified as Candidates for Intestinal Transplantation: A 3-Year Prospective Follow-Up. Gastroenterology, 2008, 135, 61-71.	1.3	105

#	Article	IF	CITATIONS
73	Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit?. Cancer Treatment Reviews, 2008, 34, 568-575.	7.7	106
74	Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1690.	7.4	236
75	Endoscopic Mucosal Improvement in Patients with Active Crohn's Disease Treated with Certolizumab Pegol. American Journal of Gastroenterology, 2008, 103, S432.	0.4	8
76	Low Risk of Irritable Bowel Syndrome after <i>Clostridium difficile </i> Infection. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 727-731.	1.7	40
77	Tackling needs for clinical nutrition at local level: The Nutri'Action campaign in France. Clinical Nutrition Supplements, 2007, 2, 33-37.	0.0	1
78	Nutritional deficiencies in patients with Crohn $\hat{E}^{1}\!\!/4$ s disease in remission. Inflammatory Bowel Diseases, 2006, 12, 185-191.	1.9	208
79	Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. Clinical Nutrition, 2006, 25, 82-90.	5.0	90
80	Monitoring of patients on home parenteral nutrition (HPN) in Europe: A questionnaire based study on monitoring practice in 42 centres. Clinical Nutrition, 2006, 25, 693-700.	5.0	41
81	Candidates for Intestinal Transplantation: A Multicenter Survey in Europe. American Journal of Gastroenterology, 2006, 101, 1633-1643.	0.4	129
82	Quand faut-il poser une gastrostomie percutanée endoscopique chez un sujet âgé�. Nutrition Clinique Et Metabolisme, 2005, 19, 126-130.	0.5	2
83	Muscle Performance in Patients With Crohn's Disease in Clinical Remission. Inflammatory Bowel Diseases, 2005, 11, 296-303.	1.9	75
84	Effects of <i>Saccharomyces boulardii </i> on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World Journal of Gastroenterology, 2005, 11, 6165.	3.3	88
85	Malnutrition is an independent factor associated with nosocomial infections. British Journal of Nutrition, 2004, 92, 105-111.	2.3	295
86	Gut changes attributed to ageing: effects on intestinal microflora. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 49-54.	2.5	94
87	Effect of steroids on energy expenditure and substrate oxidation in women with crohn's disease. American Journal of Gastroenterology, 2002, 97, 2843-2849.	0.4	26
88	Lack of adaptation to severe malnutrition in elderly patients. Clinical Nutrition, 2002, 21, 499-504.	5.0	57
89	Prise en charge nutritionnelle à domicile des malades cancéreux. Nutrition Clinique Et Metabolisme, 2001, 15, 335-342.	0.5	3
90	Outcome of Patients Treated with Home Enteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2001, 25, 203-209.	2.6	48

Xavier Hébuterne

#	Article	IF	CITATIONS
91	Energy metabolism and substrate oxidation in patients with Crohn's Disease. Nutrition, 2000, 16, 173-178.	2.4	69
92	Use of Nutritional Scores to Predict Clinical Outcomes in Chronic Diseases. Nutrition Reviews, 2000, 58, 31-38.	5 . 8	48
93	Acute Renutrition by Cyclic Enteral Nutrition in Elderly and Younger Patients. JAMA - Journal of the American Medical Association, 1995, 273, 638.	7.4	71